As the tides of the Pujiang River surge forward, so too does China's momentum in prostate cancer innovation. The 2025 Pujiang Prostate Cancer Academic Congress—held jointly with the Annual Meeting of the CSCO Prostate Cancer Committee (CSCO-PC), the Prostate Cancer Conference of the CACA Genitourinary Oncology Committee (CACA-GO), and the Annual Conference of the Chinese Prostate Cancer Consortium (CPCC)—took place in Shanghai from June 27–28. The event gathered leading experts from China and abroad to exchange the latest advances and clinical practices in prostate cancer. In an exclusive interview with Oncology Frontier – Urology Frontier, Congress Chair and Professor Dingwei Ye of Fudan University Shanghai Cancer Center shared his perspectives on the current status and future of prostate cancer care in China, along with recent innovations in surgical treatment.

The 2025 Pujiang Prostate Cancer Academic Congress, held in conjunction with the CSCO Prostate Cancer Committee (CSCO-PC) Annual Meeting, the CACA Genitourinary Oncology Committee (CACA-GO) Prostate Cancer Meeting, and the Chinese Prostate Cancer Consortium (CPCC) Annual Conference, took place in Shanghai from June 27–28. With the theme “Global Insight · Chinese Practice · Precision Breakthrough,” the event brought together leading domestic and international experts to share cutting-edge progress and clinical experience in prostate cancer. During the conference, Professor Xiaojie Bian of Fudan University Shanghai Cancer Center spoke with Oncology Frontier – Urology Frontier to discuss the current landscape and future prospects of innovative drug development for prostate cancer.